A recent phase II clinical trial (NCT00890825) compared the efficacy of selumetinib in combination with docetaxel versus docetaxel alone in pre-treated patients with KRAS mutation-positive locally advanced or metastatic non small cell lung cancer. Here, KRAS is linked to non-small cell lung carcinoma.